Publications by authors named "R Agosti"
Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results.
J Neurol
August 2024
Background: There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of life.
Objective: This 18-month interim analysis of 172 patients with episodic or chronic migraine from the SQUARE study provides first prospective insights on the impact of mandatory erenumab treatment interruption, following Swiss-reimbursement requirements, in a real-world clinical setting in Switzerland.
Findings: Recruited patients receiving 70 or 140 mg erenumab underwent treatment interruption on average 11.
Article Synopsis
- Laryngeal neuroendocrine tumors (NETs) are very rare, making up less than 1% of laryngeal cancers, and calcitonin-secreting types are even more uncommon.
- A 71-year-old woman diagnosed with a small cell undifferentiated neuroendocrine carcinoma underwent multiple treatments, including chemotherapy, which led to some initial success but later relapsed with increased calcitonin levels.
- The case highlights the difficulties in diagnosing and treating laryngeal NETs, particularly regarding the role of serum calcitonin levels in tracking disease persistence and treatment response.
Introduction: There is limited real-world evidence on the burden of migraine among patients with prior preventive treatment failure (PPTF). In the BECOME Swiss subanalysis, we aimed to assess current prevalence of PPTF in patients with migraine seen at specialised headache centres in Switzerland and burden of migraine in these patients. Furthermore, we assessed this burden in subgroups stratified by monthly migraine days (MMDs) and number of PPTFs.
View Article and Find Full Text PDFBackground: The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To complement findings from the pivotal program, this observational study was designed to collect and evaluate clinical data on the impact of erenumab on several endpoints, such as quality of life, migraine-related impairment and treatment satisfaction in a real-world setting.
Methods: An interim analysis was conducted after all patients completed 6 months of erenumab treatment.